Journal Title：Frontiers In Bioengineering And Biotechnology

The translation of new discoveries in medicine to clinical routine has never been easy. During the second half of the last century, thanks to the progress in chemistry, biochemistry and pharmacology, we have seen the development and the application of a large number of drugs and devices aimed at the treatment of symptoms, blocking unwanted pathways and, in the case of infectious diseases, fighting the micro-organisms responsible. However, we are facing, today, a dramatic change in the therapeutic approach to pathologies and diseases. Indeed, the challenge of the present and the next decade is to fully restore the physiological status of the diseased organism and to completely regenerate tissue and organs when they are so seriously affected that treatments cannot be limited to the repression of symptoms or to the repair of damage. This is being made possible thanks to the major developments made in basic cell and molecular biology, including stem cell science, growth factor delivery, gene isolation and transfection, the advances in bioengineering and nanotechnology, including development of new biomaterials, biofabrication technologies and use of bioreactors, and the big improvements in diagnostic tools and imaging of cells, tissues and organs.

In today`s world, an enhancement of communication between multidisciplinary experts, together with the promotion of joint projects and close collaborations among scientists, engineers, industry people, regulatory agencies and physicians are absolute requirements for the success of any attempt to develop and clinically apply a new biological therapy or an innovative device involving the collective use of biomaterials, cells and/or bioactive molecules. “Frontiers in Bioengineering and Biotechnology” aspires to be a forum for all people involved in the process by bridging the gap too often existing between a discovery in the basic sciences and its clinical application.

將醫(yī)學(xué)上的新發(fā)現(xiàn)轉(zhuǎn)化為臨床常規(guī)從來(lái)都不是一件容易的事。在上個(gè)世紀(jì)下半葉，由于化學(xué)、生物化學(xué)和藥理學(xué)的進(jìn)步，我們看到了大量藥物和設(shè)備的開(kāi)發(fā)和應(yīng)用，這些藥物和設(shè)備旨在治療癥狀、阻斷不必要的途徑，并在傳染病的情況下對(duì)抗導(dǎo)致疾病的微生物。然而，今天，我們正面臨著病理和疾病治療方法的巨大變化。事實(shí)上，現(xiàn)在和未來(lái)十年的挑戰(zhàn)是完全恢復(fù)患病生物體的生理狀態(tài)，并在組織和器官受到嚴(yán)重影響以至于治療不能局限于抑制癥狀或修復(fù)損傷時(shí)完全再生組織和器官。這得益于基礎(chǔ)細(xì)胞和分子生物學(xué)的重大發(fā)展，包括干細(xì)胞科學(xué)、生長(zhǎng)因子傳遞、基因分離和轉(zhuǎn)染，生物工程和納米技術(shù)的進(jìn)步，包括新生物材料的開(kāi)發(fā)、生物制造技術(shù)和生物反應(yīng)器的使用，以及診斷工具和細(xì)胞、組織和器官成像的巨大改進(jìn)。

在當(dāng)今世界，加強(qiáng)多學(xué)科專家之間的交流，促進(jìn)聯(lián)合項(xiàng)目以及科學(xué)家、工程師、行業(yè)人士、監(jiān)管機(jī)構(gòu)和醫(yī)生之間的密切合作，是成功開(kāi)發(fā)和臨床應(yīng)用新生物療法或創(chuàng)新設(shè)備（涉及生物材料、細(xì)胞和/或生物活性分子的集體使用）的絕對(duì)要求。“生物工程和生物技術(shù)前沿”希望成為參與這一過(guò)程的所有人的一個(gè)論壇，彌合基礎(chǔ)科學(xué)發(fā)現(xiàn)與其臨床應(yīng)用之間經(jīng)常存在的差距。

Frontiers In Bioengineering And Biotechnology創(chuàng)刊于2013年，由Frontiers Media S.A.出版商出版，收稿方向涵蓋Chemical Engineering - Bioengineering全領(lǐng)域，此刊是中等級(jí)別的SCI期刊，所以過(guò)審相對(duì)來(lái)講不是特別難，但是該刊專業(yè)認(rèn)可度不錯(cuò)，仍然是一本值得選擇的SCI期刊 。平均審稿速度 12 Weeks ，影響因子指數(shù)4.3，該期刊近期沒(méi)有被列入國(guó)際期刊預(yù)警名單，廣大學(xué)者值得一試。